Author

Wadzanai Matimba-Mupaya

Observed names: Matimba-Mupaya, W, Matimba-Mupaya, W., Matimba-Mupaya, Wadzanai, W Matimba-Mupaya, W. Matimba-Mupaya

Observed institutions: Betsi Cadwaladr University Health Board, University of Leicester, Newcastle upon Tyne Hospitals NHS Foundation Trust, National Institute for Health and Care Research, University of Oxford, Renewable Energy Alaska Project, NIHR Leicester Biomedical Research Centre, Canadian Critical Care Trials Group, Imperial College London, Salisbury NHS Foundation Trust, Newcastle University, University of Edinburgh

OpenAlex ID: A5063158073

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

2022 · R A Evans, O C Leavy, et al. · The Lancet Respiratory Medicine · 413

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

2021 · Hesham Abdelhady, Marwa Abdelrazik, et al. · JAMA · 210

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 146

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 136

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

2022 · Felicity Liew, Shubha Talwar, et al. · EBioMedicine · 121

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

2024 · Felicity Liew, Claudia Efstathiou, et al. · Nature Immunology · 107

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19

2023 · Simin Florescu, Delia Stanciu, et al. · JAMA · 63

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

2023 · Betty Raman, Celeste McCracken, et al. · The Lancet Respiratory Medicine · 57

Intravenous Vitamin C for Patients Hospitalized With COVID-19

2023 · The LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Simin Florescu, et al. · JAMA · 53

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

2023 · Callum Jackson, Iain D Stewart, et al. · The Lancet Respiratory Medicine · 35

Accelerated immune ageing is associated with COVID-19 disease severity

2024 · Janet M. Lord, Tonny Veenith, et al. · Immunity & Ageing · 34

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

2023 · Bang Zheng, Giulia Vivaldi, et al. · The Lancet Regional Health - Europe · 29

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

2023 · Hamish J.C. McAuley, Rachael A. Evans, et al. · EClinicalMedicine · 24

Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study

2023 · Omer Elneima, Hamish J C McAuley, et al. · International Journal of Epidemiology · 23

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury

2023 · Maxime Taquet, Zuzanna Skorniewska, et al. · Brain Communications · 14

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

Long COVID research: an update from the PHOSP-COVID Scientific Summit

2023 · Christopher E Brightling, Rachael A Evans, et al. · The Lancet Respiratory Medicine · 11

Works count: 31

Citation count: 3,709

H-index: 22

I10-index: 25